Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Depression, Anxiety
Phase Not Applicable
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine the incidence,development trajectory and risk factors of the main peripartum mental health problems as well as explore its adverse outcomes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change of prevalence of maternal prenatal depression (before 20th gestational week, after 33th gestational week and prior to delivery)
  • Change of prevalence of maternal postpartum depression in the first year after delivery (6 weeks, 6 months and 1 year after delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2012-02-01
Completion: 2038-12-31
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: true
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangzhou Women and Children's Medical Center
Principal Investigators:
  • Xiu Qiu, PhD (PRINCIPAL_INVESTIGATOR) - Guangzhou Women and Children's Medical Center
Contact Information
Study Contact:
Xiu Qiu, PhD
0086 20 38367160
qxiu0161@163.com
Dongmei Wei, MSc
0086 20 38367159
Xiu Qiu, PhD
qxiu0161@163.com
Guangzhou Women and Children's Medical Center
Interventions
N/A
Study Locations (1 sites)
Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong 510623 China
Eligibility Criteria
Inclusion Criteria: 1. Pregnant women with \<20 weeks of gestation 2. Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center 3. Permanent residents or families intended to remain in Guangzhou with their child for more than 3 years Exclusion Criteria: 1. Combined with heart disease, hypertension, diabetes or hyperthyroidism 2. Taking anti-depressants and other treatments for depression 3. Participants was in infection status when the biological samples were collected
Conditions Anxiety Disorders and Symptoms, Depressi...
Phase NA
Enrollment 1800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Digital mental health interventions are a cost-effective and efficient approach to expanding the accessibility and impact of psychological treatments; however, little guidance exists for selecting the most effective program for a given individual. In the proposed study, decision rules will develop for selecting the digital program that is most likely to be the optimal intervention for each user. These treatment recommendations can be implemented in the context of large healthcare delivery systems to improve the delivery of digital mental health interventions at scale. The overarching aim of the current study is to better understand for whom and how leading digital interventions work in a large healthcare setting. The study builds on the existing literature and follows expert recommendations by using machine learning (ML) methods to develop precision treatment rules (PTRs) for three leading digital interventions for emotional disorders (e.g., anxiety, depression, and related mental health disorders). Specifically, ML methods will be used to develop PTRs to optimize clinical outcomes and associated intervention engagement. This study will leverage a unique partnership between Boston University (BU), SilverCloud Health (SC)--a leading provider of digital mental health care--and Kaiser Permanente (KP)--one of America's leading health care providers. A clinical trial (RCT) will be conducted to evaluate the relative effectiveness of three distinct empirically supported digital mental health interventions (from SC's existing library of programs) in a sample recruited from KP primary care and other clinical settings. Data from this trial will be used to develop theoretically and empirically informed, reliable selection algorithms for managing treatment delivery decisions. Algorithms will be validated in a separate "holdout" dataset by examining whether allocation to predicted optimal treatment is associated with superior outcomes compared to allocation to a non-optimal treatment. The role of user engagement will be determined, and other mechanisms in treatment outcome.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) — This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
  • Behavioral: Space for depression — Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
  • Behavioral: Space for resilience — This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.

Primary Outcomes

  • Change from baseline well-being at week 12 (Baseline, 4-weeks following baseline, 8-weeks following baseline, and 12-weeks following baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-12
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston University Charles River Campus
Collaborators: National Institute of Mental Health (NIMH), Silver Cloud Health, Kaiser Permanente
Principal Investigators:
  • Todd Farchione, Ph.D. (PRINCIPAL_INVESTIGATOR) - Boston University Charles River Campus
Contact Information
Study Contact:
Todd Farchione, Ph.D.
(617) 353-9610
tfarchio@bu.edu
Anthony Rosellini, Ph.D.
(617) 353-9610
ajrosell@bu.edu
Todd Farchione, Ph.D.
617-353-9610
tfarchio@bu.edu
Center for Anxiety and Related Disorders
Interventions
  • Behavioral: The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) — This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
  • Behavioral: Space for depression — Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
  • Behavioral: Space for resilience — This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
Study Locations (1 sites)
Center for Anxiety and Related Disorders, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * English-speaking adults * Ages 18 or older * Have a device that can connect to the internet.
Conditions Treatment Resistant Depression (TRD)
Phase NA
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD). The investigators are currently enrolling participants who are receiving ongoing maintenance intravenous (IV) ketamine or intranasal esketamine (Spravato) treatment at the MGH Ketamine Clinic. Participation in the study will involve adding coaching sessions to your existing ketamine maintenance treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Psychedelic Integration Coaching — Participation in the study will involve adding coaching sessions to existing ketamine maintenance treatment for patients receiving ongoing maintenance IV ketamine or IN esketamine treatment at MGH's Ketamine Clinic. If participants are eligible, they will be invited to participate in 12 weekly, 50-minute one-on-one coaching sessions conducted via Zoom. These sessions are designed to help participants process and integrate their experiences with ketamine treatment, to support personal growth and symptom improvement. The coaching is non-clinical, collaborative, and participant-directed, and is provided by trained psychedelic integration coaches from the Fireside Project. Throughout the 3-month coaching period and again at a 1-month follow-up, participants will complete monthly study visits that include brief remote assessments with a study clinician, along with additional self-report questionnaires. These visits will take approximately 1 to 2 hours, depending on the time point.

Primary Outcomes

  • To assess the feasibility of adjunctive coaching during ketamine/esketamine maintenance treatment. (From enrollment to the end of treatment at Month 3)
  • To assess the acceptability of adjunctive coaching during ketamine/esketamine maintenance treatment. (From enrollment to the end of treatment at Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-17
Completion: 2028-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Fireside Project
Principal Investigators:
  • Maren Nyer, PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital and Harvard Medical School
  • Franklin King, MD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital and Harvard Medical School
  • David Mischoulon, MD/PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital and Harvard Medical School
Contact Information
Study Contact:
Maren Nyer, PhD
6176434897
mnyer@mgh.harvard.edu
Franklin King, MD
fking@mgh.harvard.edu
Maren Nyer, PhD
6176434897
mnyer@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Behavioral: Psychedelic Integration Coaching — Participation in the study will involve adding coaching sessions to existing ketamine maintenance treatment for patients receiving ongoing maintenance IV ketamine or IN esketamine treatment at MGH's Ketamine Clinic. If participants are eligible, they will be invited to participate in 12 weekly, 50-minute one-on-one coaching sessions conducted via Zoom. These sessions are designed to help participants process and integrate their experiences with ketamine treatment, to support personal growth and symptom improvement. The coaching is non-clinical, collaborative, and participant-directed, and is provided by trained psychedelic integration coaches from the Fireside Project. Throughout the 3-month coaching period and again at a 1-month follow-up, participants will complete monthly study visits that include brief remote assessments with a study clinician, along with additional self-report questionnaires. These visits will take approximately 1 to 2 hours, depending on the time point.
Study Locations (2 sites)
Massachusetts General Hospital's Depression and Clinical Research program, Boston, Massachusetts 02114 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: 1. Age 18 years or older at the time of informed consent/study enrollment. 2. Ability to understand and provide informed consent. 3. Fluent in English (spoken and written). 4. Willingness to have coaching sessions recorded via HIPAA-compliant MGB approved video-based platform. 5. Has a QIDS-SR score ≥ 11, indicating at least moderate depressive symptom severity at screening visit. 6. Lifetime diagnosis of a depressive disorder according to the MINI. 7. In the maintenance phase of ketamine or esketamine treatment, defined as the period following the initial acute treatment series (typically 2 treatments per week for 3 weeks). 8. Patients must have completed at least 3 maintenance treatments prior to screening visit with a QIDS-SR score ≥ 11 noted from EPIC medical records from the 3 most recent maintenance treatments. 9. Currently receiving maintenance IV ketamine or intranasal esketamine at the MGH Ketamine Clinic, with at least one treatment administered within the past 8 weeks, and planning to continue to be an active patient at the MGH Ketamine Clinic for the duration of the study. 10. Has established care with a mental health provider (e.g., psychiatrist, therapist, or other licensed mental health clinician), and, if outside the MGB-healthcare system, agrees to sign a Release of Information form (ROI) with the study team. Exclusion Criteria: 1. Presence of an unstable medical condition, as determined by the study clinician. 2. Significant neurocognitive impairment that impairs with individual's ability to maintain ADLs and would interfere with study participation, per study clinician judgment. 3. Newly initiated psychotherapy within the past 3 months. 4. Any condition or circumstance that, in the judgment of the Principal Investigator, makes participation unsafe or unsuitable. 5. Any psychiatric condition that is currently primary, clinically predominant to their depression, or insufficiently stable such that it would interfere with study participation, per clinician judgment. 6. Plan to switch from IV ketamine treatment to intranasal esketamine or plan to switch from intranasal esketamine to IV ketamine treatment at any point during study. 7. Suicidality determined by the judgment of the study clinicians at screen, with a plan to act in next 6 months. 8. A ≥25% reduction in QIDS total score from screen to baseline visit.
Conditions Angling, Supportive Therapeutic, Schizop...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effects of recreational fishing (angling) as a supportive therapeutic intervention in individuals diagnosed with schizophrenia. Schizophrenia is a chronic psychiatric disorder characterized by disturbances in thinking, perception, emotion, and behavior, often accompanied by negative symptoms such as social withdrawal, anhedonia, and cognitive impairment, which significantly reduce quality of life. Recreational activities, particularly those involving nature-based engagement, have been shown to support psychological well-being through stress reduction, improved attention, and enhanced mood regulation. Angling is considered a mindfulness-like recreational activity that promotes relaxation, concentration, and emotional regulation, potentially offering benefits for individuals with psychiatric conditions. In this randomized controlled study, participants with schizophrenia will engage in a structured recreational fishing program in addition to standard care. The effects of the intervention will be evaluated on biochemical serum parameters, anxiety and depression levels, and quality of life outcomes. The study also aims to assess the psychosocial well-being of participants and determine the feasibility of integrating angling as an adjunctive non-pharmacological intervention in schizophrenia care. The findings are expected to contribute to evidence-based complementary treatment approaches in psychiatric rehabilitation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: recreational fishing (angling) — Fishing will be done.

Primary Outcomes

  • The Positive and Negative Syndrome Scale (Baseline and immediately after the 8-week intervention.)
  • Quality of Life Scale for Schizophrenia Patients (Baseline and immediately after the 8-week intervention.)
  • UCLA Loneliness Scale (Baseline and immediately after the 8-week intervention.)
  • Serum Beta-Endorphin Concentration (Baseline and immediately after the 8-week intervention.)
  • Serum Serotonin Concentration (Baseline and immediately after the 8-week intervention.)
  • Serum Cortisol Concentration (Baseline and immediately after the 8-week intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-15
Completion: 2026-08-15
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Firat University
Contact Information
Study Contact:
Gülcan B Bahçecioğlu Turan
506 557 60 86
gulcanbahcecioglu@firat.edu.tr
Fırat university
Interventions
  • Behavioral: recreational fishing (angling) — Fishing will be done.
Study Locations (1 sites)
Fırat university, Elâzığ, Center 25240 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older * Able to communicate verbally * Diagnosed with schizophrenia * Able to provide written informed consent Exclusion Criteria: * Presence of comorbid psychiatric disorders other than schizophrenia * Patients in the acute psychotic (attack) phase
Conditions Anxiety Disorders, Anxiety Depression
Phase NA
Enrollment 170
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective is to evaluate the (cost-)effectiveness of exposure therapy (ET) delivered by trained mental health nurses (MHNs) in terms of anxiety symptoms and quality of life for late life anxiety disorders in primary care compared to usual care (UC). UC is not restricted, and the general practitioner (GP) is encouraged to work according to the guidelines of the Dutch College of GPs. Participants in the ET group will receive 30-minute ET sessions delivered by a trained mental health nurse, during 8 sessions within the span of 12 weeks. Participants will fill in questionnaires before, during and after treatment, with a 1-year follow-up. The main study parameters are anxiety severity, quality of life and societal costs.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Exposure therapy — The exposure therapy will be given by the mental health care nurses (MHN) working in primary care centres. In addition, there will be eight sessions spread over 12 weeks. The first session will be 60 minutes long and the rest will be 30 minutes long.
  • Behavioral: Usual Care — The Usual Care group will receive care based on the general practitioners guidelines for anxiety disorders in the primary care center. This will entail possible medication, e-learning or psycho-education, problem solving therapy or a referral to a mental health institution.

Primary Outcomes

  • Is ET performed by MHNs effective compared to UC in primary care for older adults with anxiety disorders in terms of QUALYs and symptoms of anxiety? (Pre-intervention, post-intervention (after 12 weeks of treatment), 3-month follow-up (FU), 6- month FU, 9-month FU, 12-month FU)
  • Is ET performed by MHNs cost-effective compared to UC in primary care for older adults with anxiety disorders in terms of QUALYs and symptoms of anxiety? (Pre-intervention T0, post-intervention (after 12 weeks of treatment, also knows as T9), 3-month FU, 6- month FU, 9-month FU, 12-month FU)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-12
Completion: 2028-12-19
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 170 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ProPersona
Collaborators: Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Principal Investigators:
  • Dominique NJ Rijkelijkhuizen, MSc (STUDY_CHAIR) - ProPersona
  • Özge Baturlar, MSc (STUDY_CHAIR) - ProPersona
Contact Information
Study Contact:
Gert-Jan Hendriks, Professor
+31510038897
g.hendriks@propersona.nl
Nessa Ikani, Asst. Prof.
n.ikani@tilburguniversity.edu
Tim Olde Hartman, doctor
+31624796841
tim.oldehartman@radboudumc.nl
RadboudUMC
Interventions
  • Behavioral: Exposure therapy — The exposure therapy will be given by the mental health care nurses (MHN) working in primary care centres. In addition, there will be eight sessions spread over 12 weeks. The first session will be 60 minutes long and the rest will be 30 minutes long.
  • Behavioral: Usual Care — The Usual Care group will receive care based on the general practitioners guidelines for anxiety disorders in the primary care center. This will entail possible medication, e-learning or psycho-education, problem solving therapy or a referral to a mental health institution.
Study Locations (1 sites)
RadboudUMC, Nederland, Nijmegen 6525EZ Netherlands
Eligibility Criteria
Inclusion Criteria: * A primary DSM-5 anxiety disorder using the Mini Internationaal Neuropsychiatrisch Interview (MINI). * One of the following DSM-5 anxiety disorders will be diagnosed, Generalized Anxiety Disorder, Agoraphobia, Panic Disorder or Social Anxiety Disorder. * Participants are required to be sufficient in Dutch. Exclusion Criteria: * Exclusion criteria include somatic and/or another psychiatric morbidity that could interfere with diagnosing or treatment. * Moderate to severe suicidality, which will be determined using the MINI * Chronic and interfering substance or alcohol abuse * Having received previous psychotherapy including exposure in the past year. - * Antidepressants and benzodiazepines use are allowed if on a stable dose for a minimum of 8 weeks. * Participants will be excluded if they score lower than 18 points on the MoCa (115). A score of \<18 is indicative for moderate to severe cognitive impairment. - Participants will be excluded if they are terminally ill.
Conditions Postpartum Depression (PPD), Pregnancy
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The study will seek to prospectively validate the Enlighten Device for prediction of PPD by examining true/false positive and negative rates of the test using PPD outcomes collected through 3 months postpartum; compare the accuracy of biomarkers and algorithm in determining risk for PPD in blood compared to saliva; determine the utility of a week 6 sample collection in identifying women who are currently experiencing PPD thus bringing them to clinical attention. Our population will consist of pregnant women aged 18 and older up to 33 weeks of gestation. This research involves two groups of potentially vulnerable subjects: pregnant women and their infants. Because this is a study of postpartum depression (PPD), inclusion of these two vulnerable subjects is required. The study will enroll 1000 pregnant non-adolescent women of childbearing age who meet eligibility criteria. This project will address the following Aims: Specific Aim 1: Prospective collection of true/false positive and negative PPD outcomes through 3 months postpartum. Primary Hypothesis H1a: 80% or greater of pregnant women who develop postpartum depression (PPD) by 3 months after delivery will be determined to be Biomarker Positive by the Enlighten Test in T3. Primary Hypothesis H1b: 10% or fewer of pregnant women who are determined to be Biomarker Negative by the Enlighten Test in T3 will develop PPD by 3 months after delivery. Exploratory Aim 1: Investigation of clinical factors that may be associated with false positive and false negative rates, such as: medication use, stressful life events, \& sociocultural context. Specific Aim 2: Comparison of prospective biomarker calls made in blood samples compared to saliva samples using the Enlighten Test. Primary Hypothesis H2: Biomarker calls made using blood versus saliva samples will demonstrate a high concordance rate of 75% or higher. Exploratory Aim 2: In individuals who develop PPD by 3 months postpartum, conduct an epigenome-wide study (EWAS) in saliva to identify saliva-specific epigenetic biomarkers to improve the algorithm's ability to predict PPD using saliva in the third trimester and Week 6 samples. Specific Aim 3: Determination of the utility of the Enlighten Test in identifying women currently experiencing PPD at W6 postpartum. Primary Hypothesis H3: 80% of women who meet criteria for PPD at W6 will be Biomarker Positive. Participants will be screened during the second or third trimester and enrolled during the third trimester, before week 30 weeks of gestation. Participants may self- identify through study advertisements in participating clinics, social media outlets, and community outreach efforts. Enrolled participants will undergo blood collection during their 3rd trimester completed by mobile phlebotomists in-person through ExamOne (\~27-30 weeks, a standard pregnancy-related blood collection timepoint) for completion of the Enlighten Device test, the blood-based epigenetic biomarker test. Participants…

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Diagnostic Test: Enlighten — The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results ("elevated risk" or "low risk") at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point.

Primary Outcomes

  • Percentage of Participants with True/False Positive and Negative PPD Outcomes as Assessed by the Enlighten Device (6 months postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-20
Completion: 2030-08
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Virginia
Collaborators: Mayo Clinic, Dionysus Health
Contact Information
Study Contact:
Meeta Pangtey, MPH
434-987-7367
uwp7jh@uvahealth.org
Lauren A Williamson, PhD
434-987-7369
lea6d@uvahealth.org
Interventions
  • Device: Diagnostic Test: Enlighten — The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results ("elevated risk" or "low risk") at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point.
Study Locations (1 sites)
University of Virginia, Charlottesville, Virginia 22903 United States
Eligibility Criteria
Inclusion Criteria: * subject must be pregnant (singleton pregnancy) * \<30 weeks' gestation, age 18 or above * able to provide written consent in English Exclusion Criteria: * The study team and/or PI may exclude anyone deemed unsafe to participate in the protocol.
Conditions Transcutaneous Vagus Nerve Stimulation o...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Stimulation of the vagus nerve, a parasympathetic nerve that controls the digestive, the vascular and immune systems, produces pain relief in various clinical conditions. Transmission via vagal afferents to the nucleus of the solitary tract has been proposed as the primary physiological mechanism that reduces pain intensity following vagal stimulation. Medication is one of the pillars of dealing with chronic pain, with several benefits, but also side effects. Fibromyalgia is an idiopathic chronic pain syndrome with few, effective and safe treatments. However, current research in the field of vagal innervation suggests psychophysiological and electrical ways by which the syndrome may be treated.The chronic pain symptoms of fibromyalgia patients may benefit from vagus nerve stimulation, by normalizing the autonomic and immune system dysfunction that causes their respective symptoms. However, the effects of multiple sessions of transcutaneous vagus nerve stimulation (tVNS) in fibromyalgia have not been evaluated in randomized clinical trials. The hypothesis of our study is to evaluate if the addition of transcutaneous stimulation of the auricular branch of the vagus nerves in patients with fibromyalgia, can lead to better pain control and quality of life. We will offer a 2-week treatment (14 sessions of 30 minutes) in a randomized double-blind controlled trial. The sample of the study, which will be conducted in the pain clinic of the Aretaieion University General Hospital, will be consisted of 120 patients, who will be divided into 2 groups (1st group: standard pharmacological treatment + active tVNS, 2nd group: standard pharmacological treatment + sham tVNS). The study is designed to determine, if standard pharmacological treatment combined with 14 sessions of tVNS is able to improve pain symptomatology in fibromyalgia and all symptoms of this syndrome, by using appropriate scales. This study examines a new and potentially impactful way to address a major public health issue where prevalence is high in given groups, its impact is multidimensional and treatment options are limited. The holistic treatment of chronic pain, including its neurobiological, cognitive, behavioral and psychological components, may become a valuable aid in the completion of the research project, with the ultimate aim of the study being the establishment of non-invasive stimulation of the vagus nerve for the treatment of chronic pain in clinical practice in the future.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: tVNS — tVNS L is a battery-driven electrical stimulator connected to an ear electrode which is positioned over the skin of the cymba conchae. Thus, auricular vagal stimulation will be applied using the typical ear electrodes of the tVNS® L device. tVNS will be applied over the left branch for safety reasons. For sham auricular tVNS, the anodal electrode will be placed over the center of the left ear lobe. The cathode will be placed over the antitragus. This method and these stimulation parameters have been previously used for reliable blinding in other clinical studies. Series of electrical pulses with 250 μs pulse width, 25 Hz frequency, and 28 s inter-burst interval (32 sec on/28 sec off duty cycle) will be applied in each intervention session. Auricular tVNS will be applied at 1mA - 5mA intensity for 30 min per session (1 session per day, 7 consecutive days a week, 14 sessions in total)

Primary Outcomes

  • Pain intensity and Fibromyalgia symptoms (2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-15
Completion: 2026-06-01
Eligibility
Age: 18 Years – 79 Years
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National and Kapodistrian University of Athens
Contact Information
Study Contact:
Martina Rekatsina Rekatsina, Assist Prof of ANaesthesiology
+302107286288
mrekatsina@gmail.com
Aretaieion University Hospital
MARTINA REKATSINA
Aretaieion University Hospital
Interventions
  • Device: tVNS — tVNS L is a battery-driven electrical stimulator connected to an ear electrode which is positioned over the skin of the cymba conchae. Thus, auricular vagal stimulation will be applied using the typical ear electrodes of the tVNS® L device. tVNS will be applied over the left branch for safety reasons. For sham auricular tVNS, the anodal electrode will be placed over the center of the left ear lobe. The cathode will be placed over the antitragus. This method and these stimulation parameters have been previously used for reliable blinding in other clinical studies. Series of electrical pulses with 250 μs pulse width, 25 Hz frequency, and 28 s inter-burst interval (32 sec on/28 sec off duty cycle) will be applied in each intervention session. Auricular tVNS will be applied at 1mA - 5mA intensity for 30 min per session (1 session per day, 7 consecutive days a week, 14 sessions in total)
Study Locations (1 sites)
Aretaieion University Hospital, Athens, Greece 11523 Greece
Eligibility Criteria
Inclusion Criteria * Women between 18-79 years old * Women diagnosed with Fibromyalgia according to the ACR 2016 Revised Classification Criteria * Moderate to high pain intensity according to analog pain scales (above 4 points over 10), for more than 6 months * Cognitive function sufficient to understand the experiments and follow instructions * Ability to read and understand all information on the device display. * Ability to adjust the strength of the stimulation or give feedback regarding their response to the device (feeling tingling/pulsating/pain). * Ability to comply with the recommended therapy regiment of 30 min per day. * The ear electrode needs to fit the patient. * Patients with physical or mental disabilities * The patient must be able to use the device by themselves or * The patients' caretaker can operate the device on the patient. In this case the patient --must still be able to give feedback regarding their response to the device Exclusion Criteria * Cardiac arrhythmias * Pregnancy * Serious mental disorder (dipolar disorder, schizophrenia etc.) * Prior injury to the vagus nerve * Individuals with scar tissue that may interfere with the stimulation * Presence of an electrically or magnetically activated implant
Conditions Depression in Adolescence, Anxiety
Phase NA
Enrollment 428
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this trial is to evaluate a school-based intervention designed to promote mental health among at-risk adolescents from low-income communities in Malaysia. The study will employ a two-arm, cluster randomised controlled trial design, comparing a school-based intervention to a control condition. Adolescents will be recruited from at least 20 secondary schools located in economically disadvantaged rural and urban areas of Malaysia. Assessments will take place at multiple time points: during screening, at baseline (pre-intervention), immediately after the intervention (8 weeks), and at two follow-up points-6 and 12 months post-intervention. The primary outcomes are a reduction in anxiety and depressive symptoms, along with improved mental wellbeing at the 12-month follow-up.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Super Skills for Life program — Study-Skills program will be implemented in a group format (45-60 minutes per session) in 8 weekly sessions, covering: note-taking skills, effective study strategies, and time management.
  • Behavioral: Study-Skills program — Study-Skills program will be used as a comparator intervention, which will be implemented in a group format (45-60 minutes per session) in 8 weekly sessions, covering: note-taking skills, effective study strategies, and time management.

Primary Outcomes

  • Change in adolescent's anxiety and depression (Pre-intervention, as well as at 8 weeks, and at 6 and 12 months after the intervention.)
  • Change in adolescent's wellbeing (Pre-intervention, as well as at 8 weeks, and at 6 and 12 months after the intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08
Completion: 2026-09
Eligibility
Age: 12 Years – 14 Years
Sex: ALL
Volunteers: false
Enrollment: 428 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Roehampton
Collaborators: Universiti Malaysia Sabah, University Malaysia Sarawak, Universidad Complutense de Madrid, Sunway University, Saglik Bilimleri Universitesi, University of Exeter, University of Malaya, National University of Malaysia
Contact Information
Study Contact:
Cecilia A Essau, PhD
+442083923647
c.essau@roehampton.ac.uk
Suwaibah Zakaria, PhD
+60138837732
suwaibah@ums.edu.my
Fakulti Psikologi Dan Pendidikan
Suwaibah Zakaria, PhD
Fakulti Psikologi Dan Pendidikan
Interventions
  • Behavioral: Super Skills for Life program — Study-Skills program will be implemented in a group format (45-60 minutes per session) in 8 weekly sessions, covering: note-taking skills, effective study strategies, and time management.
  • Behavioral: Study-Skills program — Study-Skills program will be used as a comparator intervention, which will be implemented in a group format (45-60 minutes per session) in 8 weekly sessions, covering: note-taking skills, effective study strategies, and time management.
Study Locations (5 sites)
Fakulti Psikologi Dan Pendidikan, Kota Kinabalu, Sabah 88400 Malaysia
Universiti Malaysia Sarawak, Kuching, Sarawak 94300 Malaysia
Universiti Kebangsaan Malaysia, Bangi, Selangor 43600 Malaysia
Universiti Malaya, Kuala Lumpur, Selangor 50603 Malaysia
Sunway University, Subang Jaya, Selangor 47500 Malaysia
Eligibility Criteria
Inclusion Criteria: 1. Adolescent (aged 12-14) who are in the first two years (Form 1 and Form 2, equivalent to year 7 and 8 in the United Kingdom school system, respectively) in lower secondary schools. 2. Adolescents score moderate to severe levels of anxiety and/or depression on the Depression Anxiety and Stress Scale-21 (DASS-21) based on the original cut-off norms (DASS-21 Anxiety scale ≥ 10 and/or DASS-21 Depression scale ≥ 14). 3. Adolescent's parent/carer provides written consent. Exclusion Criteria: (1) Being diagnosed with neurodevelopmental disorders. (2) Being diagnosed with intellectual disability. \-
Conditions Depression - Major Depressive Disorder
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to assess the feasibility of nutritional interventions in college students with depression. The main outcomes it aims to measure are: * Nutritional content, meal timing, and sleep patterns in college students with depression * Feasibility of nutritional interventions (Mediterranean Diet and Time-Restricted Eating + Mediterranean Diet) in college students with depression Researchers will compare two groups - Mediterranean Diet (Med-Diet) and Time-Restricted Eating + Mediterranean Diet (TRE + Med-Diet) - to assess adherence to the dietary interventions and overall feasibility of the study procedures. Participants will: * Complete a 2-week baseline logging diet, sleep, activity, and mood * Be randomized to Mediterranean Diet (Med-Diet) or Time-Restricted Eating + Med-Diet (TRE + Med-Diet) * Participate in dietary counseling with a registered dietitian during the 8-week intervention * Continue to log diet, wear an actigraphy device, and complete mood, sleep, and diet assessments throughout the intervention

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Mediterranean Diet — Participants will receive ongoing dietary counseling, nutritional resources, and practical tips to support adoption of a Mediterranean-style dietary pattern emphasizing healthy fats (e.g., olive oil), whole grains, fruits, vegetables, and legumes, while limiting red meat and dairy products throughout the intervention period.
  • Behavioral: Time-Restricted Eating — Participants will receive guidance to restrict daily food intake to a consistent 10-hour eating window.

Primary Outcomes

  • Sleep onset (From enrollment to the end of baseline (2 weeks))
  • Sleep offset (From enrollment to the end of baseline (2 weeks))
  • Sleep Duration (From enrollment to the end of baseline (2 weeks))
  • M10 (From enrollment to the end of baseline (2 weeks))
  • L5 (From enrollment to the end of baseline (2 weeks))
  • Relative Amplitude (From enrollment to the end of baseline (2 weeks))
  • Interdaily Stability (From enrollment to the end of baseline (2 weeks))
  • Caloric intake timing (From enrollment to the end of baseline (2 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03
Completion: 2028-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Contact Information
Study Contact:
Michael J McCarthy
858-534-8070
mmccarthy@health.ucsd.edu
Michael J McCarthy
858-534-8070
mmccarthy@health.ucsd.edu
University of California San Diego
Interventions
  • Behavioral: Mediterranean Diet — Participants will receive ongoing dietary counseling, nutritional resources, and practical tips to support adoption of a Mediterranean-style dietary pattern emphasizing healthy fats (e.g., olive oil), whole grains, fruits, vegetables, and legumes, while limiting red meat and dairy products throughout the intervention period.
  • Behavioral: Time-Restricted Eating — Participants will receive guidance to restrict daily food intake to a consistent 10-hour eating window.
Study Locations (1 sites)
University of California San Diego, La Jolla, California 92093 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years and enrolled as a college student * Symptoms of mild to moderate depression * Receiving treatment for depression or willing to receive treatment during study participation * Generally in good physical health * On a stable dose of any medication affecting weight, metabolism, or mental health Exclusion Criteria: * Elevated risk for suicide * Inability to participate safely, as determined by the study physician * Lifetime diagnosis of bipolar disorder, schizophrenia, or post-traumatic stress disorder * Current eating disorder (e.g., bulimia, anorexia nervosa, binge eating) * Current alcohol or substance use disorder * Shift work outside of class schedule in the past 30 days * Pregnancy or lactation * Treatment with an investigational drug for depression or participation in another study requiring modification of diet
Conditions Depression, MDD, Major Depressive Disord...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This pilot study evaluates the feasibility, safety, and preliminary efficacy of home-based 60Hz intermittent light therapy in adults with a major depressive episode (MDE). Participants will be randomized in a 2:1 ratio to receive either active or sham 60Hz intermittent light stimulation for 30 minutes daily (Monday through Friday) over three weeks. The light is delivered through a wearable headset. Clinical assessments will be conducted remotely at baseline, mid-point, post-treatment, and follow-up to measure changes in depressive symptoms.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: 60Hz Intermittent Light Therapy — Intermittent 60 Hz flickering white light delivered via a wearable headset.
  • Device: Sham Light Therapy — Constant white light delivered via a wearable headset.

Primary Outcomes

  • Proportion of Participants who Complete all Scheduled Sessions (Up to Week 3)
  • Average Percentage of Completed Sessions (Up to Week 3)
  • Proportion of Participants who Discontinue due to Adverse Effects (Up to Week 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-18
Completion: 2027-02-01
Eligibility
Age: 24 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: Syntropic Medical
Principal Investigators:
  • Giuseppina Pilloni, PhD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Shayna Pehel
929-455-5104
Shayna.Pehel@nyulangone.org
Giuseppina Pilloni
929-455-5317
Giuseppina.Pilloni@nyulangone.org
Interventions
  • Device: 60Hz Intermittent Light Therapy — Intermittent 60 Hz flickering white light delivered via a wearable headset.
  • Device: Sham Light Therapy — Constant white light delivered via a wearable headset.
Study Locations (1 sites)
NYU Langone Health, New York, New York 10017 United States
Eligibility Criteria
Inclusion Criteria: * Age between 24 and 65 years (inclusive)\*. * Confirmed diagnosis of Major Depressive Disorder (MDD), based on MINI interview. * Hamilton Depression Rating Scale (HDRS-17) score ≥17 at screening. * On a stable dose of antidepressant medication for at least 30 days prior to HDRS-17 screening. * No evidence of premorbid cognitive impairment, as demonstrated by a standard score \>85 on the WRAT-5 Reading Recognition Subtest. * Confirmed access to a local provider that has primary responsibility for the subjects' clinical care, and who is available for contact in case of increased subject risk due to depressive symptoms. * Able to provide informed consent and comply with study procedures. * Access to a quiet space suitable for home-based light stimulation sessions. * English speaking: All study materials and assessments are only validated in English Exclusion Criteria: * Presence of primary neurological or autoimmune disorders. * Presence of psychiatric comorbidities as determined by the MINI interview (e.g., anxiety disorders, OCD, PTSD, bipolar disorder, psychotic disorder). * Current or recent diagnosis of alcohol or substance use disorder. * History of bipolar disorder or any psychotic disorder. * Clinically significant suicidal ideation or behavior, based on clinician judgment and the Columbia-Suicide Severity Rating Scale (C-SSRS). * History of seizure disorder or epilepsy. * History of migraine, tinnitus, or photosensitivity. * Diagnosis of retinal disease, cataract, or other visual impairments that may interfere with light exposure. * Regular use of anti-inflammatory drugs or anticoagulants (e.g., clopidogrel). * Pregnancy and Breastfeeding: Currently pregnant, planning pregnancy during the study period, or breastfeeding
Conditions Anxiety, Postnatal Depression
Phase NA
Enrollment 226
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This research project aims to examine the acceptability and efficacy of a French-Canadian adaptation of a postnatal anxiety and depression program. The main question it aims to answer is: \[1\] When the adapted postnatal Internet-delivered cognitive behavioral therapy (iCBT) is added to treatment as usual (TAU) in community-based care for women with anxiety and depressive symptoms, is the iCBT+TAU condition more effective to reduce symptoms than TAU alone? Participants will: postnatal iCBT group -\> Answer questionnaires before, after (week 6) and 4 weeks after the intervention (week 10); do the 6-week non-guided iCBT program for anxiety and depressive symptoms during the postnatal period. Waitlist, TAU group -\> Answer questionnaires at enrolment, at week 6 and week 10. Participants will have access to the intervention after they complete their last questionnaires.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Postnatal anxiety and depression iCBTprogram — The overarching goal of this stand-alone program is to introduce women to CBT skills to help manage symptoms of anxiety and depression, such as psychoeducation, cognitive restructuring and problem solving, behavioural activation, graded exposure and relapse prevention. Each lesson is accompanied by practical homework and resources (e.g., medication during breastfeeding, attachment and bonding, information for entourage, sleep, self-care, intrusive thought, problem solving), and is built to be easily generalizable to a broad range of women. The three lessons must be completed within a 6-week period, with up to two weeks to complete each lesson. Participants will be notified of new lessons available via email and text message reminders. There is a 5-day lockout between lessons stopping the participants to complete the next session once a session is completed to ensure that the sessions are completed over multiple weeks to allow for revision and practice.

Primary Outcomes

  • Edinburgh Postnatal Depression Scale (French) (Week 0, Week 6, Week 10)
  • Generalised Anxiety Disorder-7 (French) (Week 0, Week 6, Week 10)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 226 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Université de Sherbrooke
Collaborators: Canadian Institutes of Health Research (CIHR), Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke, Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Centre intégré de santé et services sociaux de la Montérégie-Ouest, Centre intégré de santé et services sociaux de la Montérégie-Est, Champlain Local Health Integration Network
Principal Investigators:
  • Pasquale Roberge, PhD (PRINCIPAL_INVESTIGATOR) - Université de Sherbrooke
  • Helen-Maria Vasiliadis, PhD (PRINCIPAL_INVESTIGATOR) - Université de Sherbrooke
Contact Information
Study Contact:
Pasquale Roberge, PhD
819 821-8000
Pasquale.Roberge@USherbrooke.ca
Alexandra Chapdelaine, PhD
819-821-8000
Alexandra.Chapdelaine@USherbrooke.ca
Helen-Maria Vasiliadis, PhD
450 466-5000
Helen-Maria.Vasiliadis@USherbrooke.ca
Centre intégré de santé et services sociaux de la Montérégie-Ouest
Interventions
  • Behavioral: Postnatal anxiety and depression iCBTprogram — The overarching goal of this stand-alone program is to introduce women to CBT skills to help manage symptoms of anxiety and depression, such as psychoeducation, cognitive restructuring and problem solving, behavioural activation, graded exposure and relapse prevention. Each lesson is accompanied by practical homework and resources (e.g., medication during breastfeeding, attachment and bonding, information for entourage, sleep, self-care, intrusive thought, problem solving), and is built to be easily generalizable to a broad range of women. The three lessons must be completed within a 6-week period, with up to two weeks to complete each lesson. Participants will be notified of new lessons available via email and text message reminders. There is a 5-day lockout between lessons stopping the participants to complete the next session once a session is completed to ensure that the sessions are completed over multiple weeks to allow for revision and practice.
Study Locations (4 sites)
Centre intégré de santé et services sociaux de la Montérégie-Ouest, Châteauguay, Quebec Canada
Centre intégré de santé et services sociaux de la Montérégie-Est, Greenfield Park, Quebec Canada
Centre intégré de santé et services sociaux de la Montérégie-Centre, Longueuil, Quebec J4V 2H2 Canada
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec J1H5H3 Canada
Eligibility Criteria
Inclusion Criteria: * 18 years and older * Being within 12 months postpartum * Fluent in spoken and written French * Self-reported clinical score ≥10 for anxiety and/or depressive symptoms based on the Generalised Anxiety Disorder-7 (GAD-7) and the Edinburgh Postnatal Depression Scale 10-item scale (EPDS) * Access to a computer/tablet and internet connection * Agreement to share primary provider contact information Exclusion Criteria: * Self-reported diagnosis of schizophrenia or bipolar disorder * Current substance abuse or dependence * Current use of benzodiazepines * Beginning psychological therapy (\< 4 weeks ago) or medication (\< 8 weeks ago) for depression/anxiety * Severe depression (EPDS score ≥ 23) or active suicidal intentions (EPDS question 10 = 3, yes quite often)
Conditions Bipolar Depression
Phase PHASE1, PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This is a 2x2, within-subjects, cross-over trial to test the anti-depressant effects of acute exercise in 20 participants with bipolar depression. Participants will complete four experimental sessions, two with an exercise challenge and two with a resting control condition in a counterbalanced order. Participants will receive either 800mg of ibuprofen or placebo before exercise or rest in order to test whether blocking the inflammatory response to exercise interferes with the neural and psychological effects of exercise.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Other: Exercise Session — 30 min cycling on bicycle ergometer at 60% peak power output
  • Drug: Ibuprofen 800 mg — A single oral dose of Ibuprofen
  • Other: Rest — Resting for 30 min in chair
  • Drug: Placebo — Matched placebo

Primary Outcomes

  • Inflammation (Difference between IL-6 at baseline and two hours post intervention)
  • Neural Response to Reward Anticipation (One hour post intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-03-12
Completion: 2026-12-31
Eligibility
Age: 18 Years – 55 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Laureate Institute for Brain Research, Inc.
Contact Information
Study Contact:
Jonathan Savitz
9185025104
jsavitz@laureateinstitute.org
Jonathan Savitz, PhD
918-502-5104
jsavitz@laureateinstitute.org
Laureate Institute for Brain Research
Interventions
  • Other: Exercise Session — 30 min cycling on bicycle ergometer at 60% peak power output
  • Drug: Ibuprofen 800 mg — A single oral dose of Ibuprofen
  • Other: Rest — Resting for 30 min in chair
  • Drug: Placebo — Matched placebo
Study Locations (1 sites)
Laureate Institute for Brain Research, Tulsa, Oklahoma 74136 United States
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Has an established residence and phone 3. Agrees to and is eligible for behavioral testing, magnetic resonance imaging, and blood draws. 4. Stated willingness to comply with all study procedures and lifestyle considerations (see Section 5.3, Lifestyle Considerations) and availability for the duration of the study 5. Males and females; Age 18-55 years 6. DSM-V diagnosis of bipolar disorder 7. Has a current major depressive episode 8. Depression at enrollment of sufficient severity to score \> 11 on the QIDS 9. Be stably medicated for at least 4 weeks (a non-medicated subject may be included in the study if judged to be appropriate in the medical/psychiatric opinion of the investigator) 10. BMI between 18.5 and 35 Exclusion Criteria: 1. Diagnosis of any other major psychiatric disorder such as schizoaffective disorder, schizophrenia, or current psychotic depression 2. A history of bipolar disorder with rapid cycling 3. Concurrent manic symptoms of sufficient severity to pose a substantial risk of the development of a manic episode (\>19 on the YMRS) 4. Current drug or alcohol or substance use disorder moderate or severe, except nicotine (within 6 months for severe use disorder; 2 months for moderate use disorder) 5. Volunteers currently receiving more than 4 mood-relevant psychotropic medications in a daily regimen (since this may signify a more brittle or complex clinical state) 6. Taking any of the following medications: medications with significant interactions with ibuprofen; immune-modulating medications (e.g. oral steroids); regular use of NSAIDs (\> 3 times per week) 7. Current or prior cardiac disease, cardiac arrhythmia (e.g. supraventricular tachycardia, atrial fibrillation, ventricular fibrillation), or history of cardiac ablation therapy 8. Unstable medical condition, including significant respiratory disease (e.g., asthma, reactive airway disease (i.e., exercise induced asthma), or chronic obstructive pulmonary disease (COPD)), liver disease, hypothyroidism (i.e., condition not adequately stabilized for 3 months), or other conditions likely to require hospitalization or with a life expectancy of \< 6 months (e.g., cancer). 9. History of claustrophobia that would prevent participation in imaging scans 10. Actively suicidal, as defined by expressive ideation with a plan and intent for suicide or developing suicidal ideation that requires immediate medical or treatment intervention or a suicide attempt within the previous six months 11. Participants who endorse a history of moderate to severe traumatic brain injury (\>30 min. loss of consciousness or \>24 hours posttraumatic amnesia) or other neurocognitive disorder with evidence of neurological deficits 12. Inadequate understanding of English 13. Currently pregnant or breast-feeding; fecund women not using adequate contraceptive methods; plan to become pregnant within 12 months 14. Metal in the body (e.g. history of working as a sheet metal worker) or pacemaker which is a contra-indication to magnetic resonance imaging 15. Has epilepsy, a neuromuscular disorder, or tardive dyskinesia 16. Has a chronic infectious illness 17. Requires immediate hospitalization for psychiatric disorder 18. Requires medications for a general medical condition that contraindicate any study medication 19. Receiving or have received during the index episode vagus nerve stimulation, electroconvulsive therapy, transcranial magnetic stimulation, or other somatic treatments 20. Allergy to, or other medical contraindication to ibuprofen (e.g. stomach ulcers) 21. Symptoms of myalgic encephalomyelitis/chronic fatigue syndrome or "long-COVID". 22. Current use of medications or dietary supplements for weight or appetite control, whether prescribed or not 23. Ulcerative colitis, Crohn's disease or other autoimmune disorder (except treated hypothyroidism) 24. Activity restrictions that limit the subject's ability to engage in intense physical activity 25. Use of beta-blockers, calcium channel inhibitors, or other heart-modulating medications (e.g., amiodarone) 26. Clinically significant abnormality on EKG 27. Hypertension, hepatitis, renal dysfunction, and/or anemia of sufficient severity to pose a risk to the participant 28. Moderate or heavy smoker based on Fagerstrom 29. Resting heart rate \>100 beats per minute, systolic blood pressure \> 160 mmHg, diastolic blood pressure \> 100 mmHg 30. Clinically significant screening laboratory abnormalities not covered above 31. Any reason not listed herein that would make participation in the study hazardous